Drugs / SP-103
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04819581 | Aug 2019 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05096494 | Apr 2022 → May 2023 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096494 ↗ |
| Route | Topical | “One topical system applied to the skin on the back for 12 hours.” NCT04819581 ↗ |